Source: Eur Respir J 2004; 24: 1007-1010
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hoeper M.M., Faulenbach C., Golpon H., Winkler J., Welte T., Niedermeyer J.. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010

Member's Comments

No comment yet.

Related content which might interest you: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Source: Eur Respir J 2003; 22: 330-334 Year: 2003 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006